Announcements Trials
Browse Landscape

Status

Completed 3Unknown 2

Sponsor Class

INDUSTRY 3

Study Type

Observational 3Interventional 2

Sponsor

Conditions

Breast Neoplasms 1388Neoplasms 1168Colorectal Neoplasms 626Lung Neoplasms 562Prostatic Neoplasms 538Carcinoma, Non-Small-Cell Lung 444Carcinoma, Hepatocellular 296Stomach Neoplasms 272Pancreatic Neoplasms 270Colonic Neoplasms 264Ovarian Neoplasms 231Head and Neck Neoplasms 228Rectal Neoplasms 221Melanoma 216Multiple Myeloma 204Uterine Cervical Neoplasms 198Lymphoma 195Leukemia 193Precursor Cell Lymphoblastic Leukemia-Lymphoma 191Neoplasm Metastasis 178Carcinoma, Renal Cell 177Brain Neoplasms 174Esophageal Neoplasms 173Leukemia, Myeloid, Acute 158Urinary Bladder Neoplasms 138Recurrence 123Polycystic Ovary Syndrome 122Liver Neoplasms 119Hematologic Neoplasms 117Endometrial Neoplasms 107

Interventions

Fentanyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Observational × Breakthrough Cancer Pain × Clear all
NCT03895762 2022-05-05

OASIS

A.Menarini Asia-Pacific Holdings Pte Ltd

Completed
143 enrolled

Breakthrough Cancer Pain

NCT02899884 2019-11-22

Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain

Takeda

Completed
3,765 enrolled 10 charts

Breakthrough Cancer Pain

NCT01045603 2012-10-29

INIS

Takeda

Completed
309 enrolled

Breakthrough Cancer Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡